FDA IVD Classification – Class I, II and III Diagnostic Devices
FDA IVD classification places every in vitro diagnostic device into Class I, II or III according to its risk and intended use. The class, together with the product code and the 21 CFR regulation number, decides whether your test needs no premarket submission, a 510(k), a De Novo request or a PMA. I3CGLOBAL helps IVD manufacturers identify the right classification and pathway.
What Is FDA IVD Classification?
In vitro diagnostic products are reagents, instruments and systems intended for use in diagnosing disease or other conditions by examining specimens taken from the human body, as defined in 21 CFR 809.3. Under the Federal Food, Drug, and Cosmetic Act, IVDs are medical devices, so FDA classifies them in the same three risk classes as other devices. For the wider picture, see our FDA IVD regulatory overview.
Most IVDs are reviewed by the Office of In Vitro Diagnostics in FDA’s Center for Devices and Radiological Health (CDRH). Tests used to screen donated blood, and some HIV tests, are regulated by the Center for Biologics Evaluation and Research (CBER) instead. Knowing which centre is responsible is part of getting the classification right.
| Class | Risk | Controls | Usual premarket pathway |
|---|---|---|---|
| Class I | Low | General controls | Most are exempt from 510(k) |
| Class II | Moderate | General and special controls | 510(k), unless exempt |
| Class III | High | General controls and premarket approval | PMA |
Good to know: FDA’s 2024 rule that would have phased in oversight of laboratory developed tests (LDTs) was vacated by a federal court in March 2025, and FDA formally rescinded it in September 2025. Commercially distributed IVD kits and instruments still need FDA classification and, where required, premarket review.
How Does the FDA IVD Classification Process Work?
The FDA IVD classification process starts with the intended use, not the technology. Two tests built on the same platform can fall into different classes if one screens blood donors and the other monitors a known condition. Follow these steps for every new IVD or new claim.
- Define the intended use and indicationsState the analyte, specimen type, target population, clinical purpose (screening, diagnosis, monitoring) and setting, such as central lab, point of care or home use.
- Find the matching regulationSearch 21 CFR Parts 862, 864 and 866 for the device type that matches your intended use and technology.
- Confirm the product codeUse FDA’s Product Classification Database to confirm the three-letter product code, device class and review panel.
- Check exemptions and their limitsA 510(k) exemption does not apply in every case. Read the limitations in sections 862.9, 864.9 and 866.9 before you rely on one.
- Choose the premarket pathwayPlan a 510(k), De Novo request or PMA, and decide whether you will ask FDA for a CLIA waiver at the same time.
The general method for all device types is explained on our FDA medical device classification page. This page focuses on what is specific to IVDs.
How Do You Find an FDA IVD Product Code?
Every FDA IVD product code is a three-letter code that links a generic device type to its regulation number and class. FDA publishes the codes in its Product Classification Database, and the download files are updated every Sunday. Each record shows the device name, regulation number, device class, review panel, submission type and whether the device is 510(k) exempt or eligible for third-party review.
IVD product codes sit in six review panels. Searching by panel narrows the list quickly:
| Review panel code | Panel | Typical IVDs |
|---|---|---|
| CH | Clinical chemistry | Glucose, HbA1c, electrolytes, enzymes, lipids |
| TX | Clinical toxicology | Drugs of abuse, therapeutic drug monitoring |
| HE | Hematology | Cell counters, coagulation tests, blood typing reagents |
| PA | Pathology | Specimen stains, cytology and tissue-based tests |
| IM | Immunology | Tumour markers, autoantibodies, allergy tests |
| MI | Microbiology | Bacterial and viral detection, antimicrobial susceptibility |
If no existing product code matches your intended use, your IVD may be a new device type. In that case FDA will usually expect a De Novo request rather than a 510(k).
FDA IVD Classification Under 21 CFR 862, 864 and 866
Three parts of Title 21 of the Code of Federal Regulations hold almost all IVD device types. Each regulation describes the device, gives its class and, for Class II, often names the special controls you must meet.
| 21 CFR part | Covers | Examples |
|---|---|---|
| Part 862 | Clinical chemistry and clinical toxicology devices | Glucose test systems, hemoglobin A1c test systems (862.1373, Class II), drugs of abuse tests |
| Part 864 | Hematology and pathology devices | Coagulation tests, automated cell counters, general purpose reagents (864.4010), analyte specific reagents (864.4020) |
| Part 866 | Immunology and microbiology devices | Infectious disease serology and nucleic acid tests, tumour markers, allergen-specific IgE tests |
All IVDs must also meet the labeling rules in 21 CFR 809.10, whatever their class. For kit and non-kit products, see our guide to IVD kits and non-kits.
How Are IVD Reagents and Instruments Classified?
FDA classifies IVD reagents and instruments by how they are used, not only by what they are. The same chemical can be a general purpose reagent, an analyte specific reagent or part of a cleared test system, each with different requirements.
| Product | Regulation | How FDA treats it |
|---|---|---|
| General purpose reagents (GPRs) | 21 CFR 864.4010 | Class I, exempt from 510(k); for general laboratory use, not labeled for a specific test |
| Analyte specific reagents (ASRs) | 21 CFR 864.4020 | Building blocks for laboratory tests; most are Class I and exempt, but some are Class II or III; restricted sale and labeling rules in 21 CFR 809.30 |
| Test kits and systems | Parts 862, 864 or 866 | Classified by the test’s intended use, together with their calibrators and controls |
| IVD instruments | Parts 862, 864 or 866 | Often classified with the assay they run; general laboratory equipment labeled for medical use is usually Class I |
Products labeled “For Research Use Only” or “For Investigational Use Only” are covered by 21 CFR 809.10(c) and must not be promoted for clinical diagnosis. If you plan to move from RUO to clinical use, the product needs a full FDA IVD classification and, where required, 510(k) clearance.
Class I, II and III IVD Examples and Requirements
The examples below show how FDA IVD classification works in practice. Always confirm the exact regulation and product code for your own intended use, because claims change the class.
Class I IVDs
Low-risk products under general controls, such as general purpose reagents and most analyte specific reagents. Most Class I IVDs are exempt from 510(k), but the exemption limits in 862.9, 864.9 and 866.9 can remove it, for example for some home-use or cancer-related claims.
Class II IVDs
Moderate-risk tests under general and special controls, such as glucose and HbA1c test systems, coagulation tests and many infectious disease tests. Most need a 510(k) that shows substantial equivalence to a predicate device.
Class III IVDs
High-risk tests where a wrong result could cause serious harm, such as many companion diagnostics and some tests for serious infectious diseases. These need a premarket approval (PMA). See our guide to premarket approvals.
What usually keeps an IVD in a lower class
- Use by trained laboratory staff
- Results confirmed by other tests or clinical findings
- A well-established analyte and method
What usually moves an IVD to a higher class
- Results that directly decide treatment
- Blood donor or transfusion screening
- Diagnosis of serious infections where a wrong result is life-threatening
What If Your IVD Has No Predicate?
A novel IVD with no legally marketed predicate is automatically Class III. If its risk is low to moderate, you can ask FDA to classify it into Class I or II through a De Novo request. A granted De Novo creates a new regulation and product code that later tests can use as a predicate. For the process, timelines and data FDA expects, see our De Novo submission guide.
FDA Classification for Molecular Diagnostics, Immunoassays and Rapid Tests
FDA diagnostic test classification depends on the claim more than the technology, but each test family has typical patterns:
| Test type | Typical class | What to watch |
|---|---|---|
| Molecular diagnostics (PCR, isothermal, NGS) | Mostly Class II under Part 866 | Special controls often require specific analytical and clinical studies; companion diagnostics are usually Class III |
| Immunoassays (ELISA, chemiluminescence) | Mostly Class II under Parts 862 and 866 | Calibrators and controls may have their own regulations and product codes |
| Rapid and point-of-care tests | Usually Class II | Near-patient use can remove a 510(k) exemption; many also seek a CLIA waiver |
| IVD software | Follows the IVD it supports | Software that analyses test results is reviewed as part of the IVD or under its own product code |
FDA Classification of Blood Glucose Monitoring Systems
Glucose test systems are classified under 21 CFR 862.1345 as Class II devices, so a 510(k) is needed. FDA has separate guidance documents for self-monitoring blood glucose systems for over-the-counter use and for blood glucose monitoring systems for prescription point-of-care use, with different accuracy expectations. Integrated continuous glucose monitoring systems have their own regulation, 21 CFR 862.1355, also in Class II.
This is a good example of why the setting matters: the same analyte can have different performance requirements depending on who uses the test and where.
FDA IVD Classification vs CLIA Categorization
FDA risk classification and CLIA categorization are two different things. The class decides the premarket pathway. The CLIA category decides which laboratories may run the test. FDA assigns the CLIA category when it clears or approves a test, or later on request.
| FDA classification | CLIA categorization | |
|---|---|---|
| What it measures | Risk of the device to patients | Complexity of performing the test |
| Categories | Class I, II or III | Waived, moderate complexity or high complexity |
| Decides | 510(k), De Novo or PMA | Which labs can use the test |
| Legal basis | FD&C Act and 21 CFR | Clinical Laboratory Improvement Amendments of 1988 |
Tests intended for clinics, pharmacies or home use usually need a CLIA waiver. Read more about CLIA waiver consulting and the dual 510(k) and CLIA waiver route.
What Clinical Evidence Does an IVD Need?
Once the class is clear, the submission needs evidence to match. Most IVD 510(k)s include analytical performance studies, such as precision, accuracy, limit of detection, interference and stability, and clinical performance data, such as sensitivity and specificity against a reference method. Special controls for Class II IVDs often list the exact studies FDA expects. See our guide to FDA IVD clinical evidence and the 510(k) IVD submission workflow.
Common FDA IVD Classification Mistakes
Most classification problems we see come from a few repeated errors. Each one can lead to a refused 510(k), extra studies or a request for a different pathway.
- Choosing a product code by technology instead of intended use
- Relying on a 510(k) exemption without reading the limitations in 862.9, 864.9 or 866.9
- Picking a predicate device with a different intended use or specimen type
- Adding home-use or point-of-care claims late in development
- Ignoring the special controls listed in the regulation until the submission stage
- Assuming the CLIA category will follow automatically from the FDA class
A short Pre-Submission meeting with FDA, prepared with our US FDA consultants, can confirm the classification before you commit to studies. See also our FDA 510(k) fees guide for budgeting.
How I3CGLOBAL Supports FDA IVD Classification
Our FDA IVD classification consulting gives you a written, evidence-based classification before you spend money on studies. As your FDA IVD classification consultant, we work through the same steps FDA reviewers use and document every decision.
- Intended use and indications review
- FDA IVD product code classification and regulation search
- 510(k) exemption and limitation analysis
- Predicate search or De Novo strategy
- CLIA categorization and waiver planning
- Pre-Submission (Q-Submission) questions to confirm classification with FDA
We then support the full submission with our FDA 510(k) consultants.
Work with I3CGLOBAL
Get Your FDA IVD Classification Right First Time
A wrong product code can mean the wrong predicate, missing studies and months of delay. Send us your intended use and we will confirm the regulation, product code, class and pathway for your IVD.
- Written classification rationale
- Product code and predicate search
- 510(k), De Novo, PMA and CLIA planning
Request an FDA IVD proposal
Share your test description, intended use and target market date, and we will come back with a proposal.
FAQs
FDA IVD Classification: Frequently Asked Questions
What is FDA IVD classification?
FDA IVD classification is the process of placing an in vitro diagnostic device into Class I, II or III based on its risk and intended use. The class, product code and 21 CFR regulation number together decide the premarket pathway.
Which regulations cover FDA IVD classification?
Most IVD device types are classified in 21 CFR Part 862 (clinical chemistry and toxicology), Part 864 (hematology and pathology) and Part 866 (immunology and microbiology). Labeling for all IVDs is covered by 21 CFR 809.10.
How do I find the FDA product code for my IVD?
Search FDA’s Product Classification Database by device name, regulation number or review panel (CH, TX, HE, PA, IM or MI). The record shows the class, submission type and 510(k) exemption status. See our FDA medical device classification guide for the general search method.
Are Class I IVDs exempt from 510(k)?
Most are, but not all. Read the limitations of exemptions in 21 CFR 862.9, 864.9 and 866.9. Some claims, such as certain home-use or cancer-related uses, remove the exemption.
Is FDA IVD classification the same as CLIA categorization?
No. FDA classification measures risk and decides the premarket pathway. CLIA categorization measures test complexity and decides which laboratories can run the test: waived, moderate complexity or high complexity.
What if no product code matches my IVD?
Your IVD is probably a new device type. It is Class III by default, and you can ask FDA to classify it into Class I or II through a De Novo request if its risk is low to moderate.
Do laboratory developed tests need FDA classification?
FDA’s 2024 LDT rule was vacated by a federal court in March 2025 and rescinded by FDA in September 2025. IVD kits and instruments sold to laboratories still need FDA classification and, where required, premarket review.
Can FDA confirm my IVD classification before I submit?
Yes. You can ask classification questions in a Pre-Submission (Q-Submission), or request a formal classification through a 513(g) request for information.
